Abstract: Murine monoclonal antibodies specific to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). The monoclonal antibodies specifically bind to TdT in a wide variety of mammalian cells including human, mouse, rat, rabbit and bovine origin. The monoclonal antibodies are secreted by hybridoma cell lines derived from fusion of murine plasmacytoma cells with splenocytes from mice immunized with TdT from bovine thymus cells. The monoclonal antibodies can detect small numbers of TdT-positive cells from monitoring of TdT-positive leukemias and lymphomas in multple species, including human.

Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.

Abstract: Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, K1, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.

Abstract: Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as therapeutic methods employing the cell suspensions.

Abstract: Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed.

Abstract: Monoclonal antibodies effective in preventing infectious bursal disease in chickens, by neutralizing one or more virus strains thereof, have been isolated and obtained from deposited hybridomas. Vaccination of an entire poultry population with a vaccine prepared from these monoclonal antibodies gives a uniform level of protection against all strains of infectious bursal disease tested. The monoclonal antibodies were effective in inducing priming for an active anti-viral response in a heterologous host.

Abstract: Monoclonal antibodies specific for the high affinity (72 K.D.) F.sub.c receptor on human monocytes are diclosed. The monoclonal antibodies do not block normal IgG binding to the receptor.

Abstract: Human T-T hybridomas are made by fusing an azaserine-hypoxanthine (AH) sensitive T leukemia cell line, preferably the AH-sensitive mutant of the Jurkat leukemia line identified as J3R7, with normal T cells and culturing the fusion product in a selective AH medium. Stable, interleukin-2 (IL-2)-producing human T-T hybridomas were made by this process.

Abstract: Antigens characteristic of all species of Listeria except L. denitrificans comprising proteins found in Listeria heat extracts, the major antigen having a molecular weight of from about 30 to about 38KD and comprising three immunogenically different epitopes and others comprising proteins having a molecular weight range of approximately 17KD to the major antigen and comprising an epitope immunoreactive with antibodies that are also reactive with one of the three epitopes on the 30 to about 38KD protein. The invention also comprises mouse monoclonal antibodies specifically reactive with the identified epitopes on these antigens.

Abstract: Murine hybridomas are disclosed which were constructed by fusing spleen cells from BALB/c mice immunized with soluble crystal protein from Bacillus thuringiensis subsp. israelensis (B.t.i.) to the murine myeloma cell line SP2/0-AG14. An ELISA (enzyme-linked immunosorbent assay) method for detection of antibodies specific for crystal protein of B.t.i. was modified to produce 100- to 1,000-fold increased sensitivity and was used to identify hybridomas secreting monoclonal antibody specific for the B.t.i. crystal protein. Analysis of the hybridoma culture supernatant fluid indicated production of monoclonal IgG3 antibodies, specific for the 68,000 dalton protein presumed to be the insecticidal delta-endotoxin of B.t.i.

Abstract: Monoclonal antibodies specific for Mycoplasma pneumoniae determinants and their use in the diagnosis of mycoplasma pneumoniae and purification of a protein determinant of M. pneumoniae.

Abstract: The present invention is directed to monoclonal antibodies and hybridomas which produce them, which react with IgE when it is unbound and thereby inhibit IgE binding to mast cells, and react with IgE when it is bound to the B-cell FcE receptor, but do not react with IgE when it is bound to the mast cell FcE receptor.

Abstract: In body fluids containing saliva alpha amylase and pancreatic alpha amylase, pancreatic alpha amylase is determined with a monoclonal antibody which specifically binds but does not inhibit saliva alpha amylase and which has a cross-reactivity of 5% or less toward pancreatic alpha amylase. The monoclonal antibody binds salvia alpha amylase to form a complex which is separated to permit determining pancreatic alpha amylase with an amylase detection system. The complex may be separated by precipitating with a precipitating agent such as an anti-antibody or protein A, or by immobilizing the monoclonal antibody on a solid carrier.

Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

Abstract: A mouse-human chimaeric immunoglobulin heavy chain comprising (a) the amino acid sequence of a mouse immunoglobulin heavy chain variable region and (b) the amino acid sequence of a human immunoglobulin heavy chain constant region and reacting specifically with human common acute lympohocytic leukemia antigen and a chimaeric DNA fragment which encodes the amino acid sequence of the above mouse-human chimaeric immunoglobulin heavy chain.

Abstract: Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.

Abstract: A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils. The monoclonal antibody has no reactivity with other human peripheral blood cells and virtually no reactivity with granulocyte precursors or other cells in bone marrow. Further, there is no reactivity with human acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using highly purified human granulocytes as the immunization agent. The monoclonal antibody further is characterized by its capability of being used to enumerate and isolate neutrophils in normal peripheral blood and patients with acute leukemia.

Abstract: Monoclonal antibodies demonstrating reactivity to genus-specific epitopes present on outer membrane proteins of bacteria of the genus Legionella and hybridomas for secreting the antibodies are disclosed.

Abstract: Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.

Abstract: A monoclonal anti-idiotypic antibody specific to a human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG.sub.1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.

Abstract: Monoclonal antibodies specific for the 8R,6R- and 8S,6S-stereoisomers of 3-(2-deoxy-.beta.-D-erythropentofuransyl)-5,6,7,8-tetrahydro-8-hydroxy-6-m ethylpyrimido[1,2-a]purine-10(3H)one were produced. These cyclic 1,N.sup.2 -propanodeoxyguanosines are formed in DNA exposed to crotonaldehyde in vitro. Three of the four antibodies were most specific for one stereoisomer while the fourth was most specific for the other stereoisomer. Fifty % inhibition of binding in an enzyme-linked immunoabsorbent assay could be achieved with 0.2 picomol of either stereoisomer. A high-pressure liquid chromatography-enzyme-linked immunoabsorbent assay using two of these antibodies and capable of detecting 0.5 .mu.mol of 1,N.sup.2 -propanodeoxyguanosine per mol of deoxyguanosine was developed. The method was validated by comparison to results obtained with fluorescence assay.

Abstract: The invention relates to a method of screening for fibrin clot-specific monoclonal antibodies and to the monoclonal antibodies screened by this method. The invention also relates to immundiagnostic and immunotherapeutic applications of the screened fibrin clot-specific monoclonal antibodies.

Abstract: A human-human hybridoma is formed by subjecting a transformed human cell to a proliferaton inhibitory treatment and then fusing the thus-treated human cell with a human antibody producing cell. A desired clone may be selected from the resultant fused cells by using an anti-HLA antibody.

Abstract: Monoclonal antibodies to angiotensin II and the continuous hybrid monoclonal cell lines for their production are provided. These antibodies are useful in the diagnosis and treatment of angiotensin II-induced hypertension.

Abstract: Monoclonal antibodies capable of immunoprecipitating labeled dihydropyridine receptor material from digitonin-solubilized skeletal muscle triads are disclosed. Said antibodies recognize a 170,000 dalton protein subunit of the dihydropyridine receptor.

Abstract: A method of determining CK-MB isoenzyme in a biological fluid is disclosed which comprises subjecting a sample of said fluid to an assay system which includes incubating with monoclonal antibody specific to CK-MB isoenzyme, but not reactive with CK-MM or CK-BB. Methods for preparing antibodies with these characteristics and cell lines producing them are also disclosed.

Abstract: The invention describes a new process for the production of anti-viral diagnostics, as well as an example of one antibody useful in detecting a wide variety of pathogenically important alphaviruses. The process includes, but is not limited to, the isolation of monoclonal antibodies directed against internal viral components. Such antibodies may be generated by conventional immunization in vivo or in vitro using subviral particles or synthetic peptides corresponding to specific viral proteins. Alternatively, synthetic peptides derived from the cytoplasmic domains of envelope proteins may be used to elicit monoclonal idiotypic and anti-idiotypic antibodies following immunization in vitro and/or in vivo.The anti-alphavirus antibody included in the invention is an example of the type of reagent produced. It was produced as an anti-idiotype against monoclonal antibodies to a synthetic peptide derived from Semliki Forest virus.

Abstract: Two novel cell lines, ATCC #HB-8963 and ATCC #HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease inhibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Ag14 myeloma cells. Diagnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.

Abstract: A method is disclosed for detecting the presence of HTLV III infected cells in a medium. The method comprises contacting the medium with monoclonal antibodies against an antigen produced as a result of the infection and detecting the binding of the antibodies to the antigen. The antigen may be a gene product of the HTLV III virus or may be bound to such gene product. On the other hand the antigen may not be a viral gene product but may be produced as a result of the infection and may further be bound to a lymphocyte. The medium may be a human body fluid or a culture medium. A particular embodiment of the present method involves a method for determining the presence of a AIDS virus in a person. The method comprises combining a sample of a body fluid from the person with a monoclonal antibody that binds to an antigen produced as a result of the infection and detecting the binding of the monoclonal antibody to the antigen. The presence of the binding indicates the presence of a AIDS virus infection.

Abstract: Monoclonal antibodies reactive with oncogenic and activated ras p21 proteins containing glutamic acid, arginine or valine at position 12 and unreactive with normal ras p21 proteins containing glycine at position 12. The antibodies are secreted by hybridomas obtained by immunizing mice with synthetic dodecapeptides corresponding in amino acid sequence to positions 5-16 of normal ras p21 proteins, except having glutamic acid, arginine or valine in place of glycine at position 12. The antibodies and Fab fragments thereof are useful for diagnosis, staging and classification of malignant and premalignant lesions.

Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.

Abstract: A method for distinguishing between NK cells and T lymphocytes is provided, which comprises contacting a sample containing lymphocytes with a first reagent comprising anti-CD3 and a first detectable label and a second reagent comprising a mixture of anti-CD16 and anti-GP160 (Leu-19) both labeled with a second detectable label, and identifying cells that react with the reagents, whereby cells that react with the first reagent are identified as T lymphocytes, and cells that react only with the second reagent are identified as NK cells. Cells that react with both reagents are identified as a unique subset of T lymphocytes some of which may mediate MHC unrestricted cytolysis.

Abstract: Antibody defining structure present in fibronectins from tumors and fetal tissues but absent in fibronectins from normal adult tissues and plasma; useful for diagnosing and treating human cancers.

Abstract: A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

Abstract: The present invention is concerned with novel monoclonal antibodies specific for an antigenic site on a protein characteristic of a human basal cell and a malignant squamous cell. The antibodies do not bind to mesenchymal cells such as fibroblasts and endothelial cells. The protein on the cell surface which binds to one of the antibodies has a molecular weight of about 120,000 as determined by one dimensional gel electrophoresis. The antibodies find use in diagnostic methods such as the detection of malignant cells, e.g., the detection of residual tumor cells in skin subjected to microscopically-controlled surgery.

Abstract: Monoclonal antibodies which demonstrate specific reactivity to cholesterol and methods for the detection of high levels of cholesterol by contacting biological specimens containing cholesterol with the monoclonal antibodies and measuring the formation of antigen-antibody complexes by immunosorbent assay.

Abstract: There are provided monoclonal antibodies which react with human oncofetal ferritin and which do not react with human spleen ferritin or with liver ferritin; there are also provided monoclonal antibodies which react both with human placenta oncofetal ferritin and with human adult spleen ferritin. There is provided a process for producing clones producing such antibodies and such clones, and an assay for the detection of human breast cancer based on the determination of oncofetal ferritin, which assay is based on such monoclonal antibodies.

Abstract: The present invention provides a specific antibody against heart muscle light chains (HMLC) with a cross-reactivity against skeletal muscle light chains (SMLC) of less than 5%. The present invention also provides a process for the preparation of this specific antibody, wherein a mammal is immunized with HMLC I and/or HMLC II and the crude serum is recovered and subjected to an immunosorptive purification on an SMLC immune adsorbent based on silicate. Furthermore, the present invention provides a reagent for the determination of HMLC which contains antibodies against HMLC according to the present invention.

Abstract: Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that are characterized by enrichment in mono-, di-, or trifucosylated type 2 chain structure. As such, the antibodies produced by the hybridoma cell lines are useful for diagnosis and treatment of human cancer. Also disclosed is an improved method of raising hybridoma cell lines by selecting the hybridomas by positive reactivity with one or more fucosylated type 2 chain structures selected from the group consisting of III.sup.3 FucnLc.sub.4, V.sup.3 FucnLc.sub.6, III.sup.3 FucnLc.sub.6, III.sup.3 V.sup.3 Fuc.sub.2 nLc.sub.6, and III.sup.3 V.sup.3 VII.sup.3 Fuc.sub.n nLc.sub.8.

Abstract: A specific hybridoma cell line produces monoclonal antibodies which are effective in detecting carcinoembryonic antigens (CEA). The specific hydribome line and monoclonal antibodes are designated as T84.66-A3.1-H11. The monoclonal antibodies are preferably applied to tissues and fluids to detect the degree of binding of such monoclonal antibodies to such carcinoembryonic antigens.

Abstract: A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils and eosinophils and exhibiting no specificity for lymphocytes, basophils and monocytes. Further there is noreactivity with acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using human granulocytes as the immunization agent. The monoclonal antibody further is capable of being used to enumerate and isolate neutrophils in normal peripheral blood and possibly in blood of patients with acute leukemia.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.

Abstract: Monoclonal antibodies specifically immunologically reactive to thiol-modified glutathione and hybridoma cell lines producing such monoclonal antibodies. A method of producing antibodies specifically immunologically reactive with reduced glutathione by immunizing an animal using a thiol-modified glutathione, for example, a glutathione-N-ethylmaleimide-keyhole limpet hemocyanin conjugate. A method of utilizing the antibodies produced to quantitate the amount of reduced glutathione in a biological sample, to monitor glutathione-associated conditions, to monitor the formation of normal metabolic intermediates and to monitor the detoxification of foreign compounds.

Abstract: This invention relates to the production of antibodies to angiogenin or to fragments thereof and to methods of inhibiting angiogenesis in mammals by administering to mammals such antibodies or Fab fragments thereof so as to inhibit angiogenic activity. In addition, this invention relates to pharmaceutical compositions comprising therapeutically effective amounts of antibody that are immunologically reactive with angiogenin and which can be administered to inhibit angiogenesis.

Abstract: A monoclonal antibody which specifically binds to the human IL-2 receptor, and a hybridoma which produces the antibody, are disclosed.

Abstract: Monoclonal antibodies, and hybridoma cell lines for their production, that bind with a high degree of specificity proteins associated with HTLV-III virus are presently disclosed. In particular, transmembrane envelope glycoprotein gp41 (41,000 dalton molecular size), major core antigen p24 (24,000 dalton molecular size), and p17 protein (17,000 dalton molecular size) are disclosed. The proteins to which the present monoclonal antibodies respond are essentially antigenically distinct from HTLV-I and HTLV-II. SVM-16 is an IgM monoclonal antibody, SVM-23 is an IgG.sub.2 monoclonal antibody, and SVM-26 is an IgG.sub.1 monoclonal antibody, all of which bind to p24. SVM-25 is an IgG.sub.1 monoclonal antibody binding gp41, and SVM-33 is an IgG.sub.1 monoclonal antibody binding p17. All the monoclonal antibodies of the present invention are produced in hybridoma cells prepared by fusing myeloma cells with spleen cells from mammals, such as mice, immunized with lysates of purified virus.

Abstract: There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatty acid or a soluble ester, alcohol or a salt thereof for a sufficient period of time to inactivate virus contained therein.

Abstract: Murine monoclonal antibodies specific to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). The monoclonal antibodies specifically bind to TdT in a wide variety of mammalian cells including human, mouse, rat, rabbit and bovine origin. The monoclonal antibodies are secreted by hybridoma cells derived from fusion of murine plasmacytoma cells with splenocytes from mice immunized with TdT from bovine thymus cells. The monoclonal antibodies can detect small numbers of TdT-positive cells for monitoring of TdT-positive leukemias and lymphomas in multiple species, including human.

Abstract: Monoclonal antibodies reactive with epiglycanin.

Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75,This invention was supported in part by Grants No. CA-15126 and CA-15437 from the National Cancer Institute, U.S. Public Health Service.